Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2014

01-02-2014 | Breast Oncology

AQP5 Expression Predicts Survival in Patients with Early Breast Cancer

Authors: Soo Jung Lee, MD, PhD, Yee Soo Chae, MD, PhD, Jong Gwang Kim, MD, PhD, Wan Wook Kim, MD, Jin Hyang Jung, MD, PhD, Ho Yong Park, MD, PhD, Ji Yun Jeong, MD, Ji-Young Park, MD, PhD, Hyun Jun Jung, PhD, Tae-Hwan Kwon, MD, PhD

Published in: Annals of Surgical Oncology | Issue 2/2014

Login to get access

Abstract

Background

Our previous study showed the association of aquaporin 5 (AQP5) up-regulation with cancer proliferation and migration in estrogen receptor (ER)-positive breast cancer cell line (MCF-7) and with unfavorable prognosis in a small number of patients with breast cancer. Accordingly, we analyzed the prognostic impact of AQP5 expression in a large number of patients with early breast cancer (EBC).

Methods

AQP5 expression was investigated on the basis of the immunohistochemistry of tissue microarray specimens from 447 EBC patients who underwent surgery between 2003 and 2008. We scored the staining intensity (0 through 3) and percentage of positive tumor cells (0 through 4), and the staining score was defined as sum of these scores used to categorize the AQP5 expression as negative (0 through 2), weak (3 through 5), or strong (6 or more).

Results

A total of 267 (59.7 %) patients were identified as AQP5-positive (staining score >2), including 123 (27.5 %) cases of strong expression (stating score >5). In a univariate analysis, AQP5 overexpression was significantly associated with survival for the patients with ER/progesterone receptor (PR)-positive and human epidermal growth factor receptor 2 (HER2)-overexpressed EBC. Moreover, a multivariate survival analysis revealed that AQP5 overexpression was an independent prognostic marker of survival for the EBC patients, which was prominent in patients with ER/PR-positive tumor. However, no difference in AQP5 expression was observed on the basis of patient and tumor characteristics.

Conclusions

AQP5 expression in tumor tissue can be considered a prognostic marker in patients with EBC after curative surgery.
Literature
1.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.CrossRef
2.
Parisi M, Amodeo G, Capurro C, et al. Biophysical properties of epithelial water channels. Biophys Chem. 1997;68:255–63.PubMedCrossRef
3.
4.
Rojek AM, Skowronski MT, Fuchtbauer EM, et al. Defective glycerol metabolism in aquaporin 9 (AQP9) knockout mice. Proc Natl Acad Sci USA. 2007;104:3609–14.PubMedCrossRef
5.
Hoque MO, Soria JC, Woo J, et al. Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth. Am J Pathol. 2006;168:1345–53.PubMedCrossRef
6.
Liu W, Wang K, Gong K, et al. Epidermal growth factor enhances MPC-83 pancreatic cancer cell migration through the upregulation of aquaporin 3. Mol Med Rep. 2012;6:607–10.PubMed
7.
Nico B, Annese T, Tamma R, et al. Aquaporin-4 expression in primary human central nervous system lymphomas correlates with tumour cell proliferation and phenotypic heterogeneity of the vessel wall. Eur J Cancer. 2012;48:772–81.PubMedCrossRef
8.
9.
10.
Kang SK, Chae YK, Woo J, et al. Role of human aquaporin 5 in colorectal carcinogenesis. Am J Pathol. 2008;173:518–25.PubMedCrossRef
11.
Jung HJ, Park JY, Jeon HS, Kwon TH. Aquaporin-5: a marker protein for proliferation and migration of human breast cancer cells. PLoS One. 2011;6:e28492.PubMedCentralPubMedCrossRef
12.
13.
Zhang ZQ, Zhu ZX, Bai CX. Lung fluorescence imaging to evaluate tumor metastasis induced by AQP5 expression in murine model. Med Oncol. 2012;29:205–11.PubMedCrossRef
14.
Saadoun S, Papadopoulos MC, Hara-Chikuma M, Verkman AS. Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature. 2005;434(7034):786–92.PubMedCrossRef
15.
Watanabe T, Fujii T, Oya T, et al. Involvement of aquaporin-5 in differentiation of human gastric cancer cells. J Physiol Sci. 2009;59:113–22.PubMedCrossRef
16.
Yang J, Yan C, Zheng W, Chen X. Proliferation inhibition of cisplatin and aquaporin 5 expression in human ovarian cancer cell CAOV3. Arch Gynecol Obstet. 2012;285:239–45.PubMedCrossRef
17.
Wang W, Li Q, Yang T, et al. Expression of AQP5 and AQP8 in human colorectal carcinoma and their clinical significance. World J Surg Oncol. 2012;10:242.PubMedCentralPubMedCrossRef
18.
Yang JH, Shi YF, Cheng Q, Deng L. Expression and localization of aquaporin-5 in the epithelial ovarian tumors. Gynecol Oncol. 2006;100:294–9.PubMedCrossRef
19.
Chen XJ, Yang JH, Zheng W. [Effect of topotecan on expression of aquaporin protein 5 and nuclear factor-kappaB in ovarian cancer SKOV3 cells]. Ai Zheng. 2009;28:856–60.PubMedCrossRef
20.
21.
Green M, Raina V. Epidemiology, screening and diagnosis of breast cancer in the Asia-Pacific region: current perspectives and important considerations. Asia Pacific J Clin Oncol. 2008;4:S5–S13.CrossRef
22.
Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212–20.PubMedCrossRef
23.
de Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96:1504–13.PubMedCentralPubMedCrossRef
24.
Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist. 2007;12:631–5.PubMedCrossRef
25.
Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer. 2007;109:1011–8.PubMedCrossRef
26.
Mook S, Schmidt MK, Weigelt B, et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol. 2010;21:717–22.PubMedCrossRef
27.
Montagna E, Maisonneuve P, Rotmensz N, et al. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer. 2013;13(1):31–9.PubMedCrossRef
28.
Metzger-Filho O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 2012;30:1879–87.PubMedCrossRef
29.
Towne JE, Krane CM, Bachurski CJ, Menon AG. Tumor necrosis factor-alpha inhibits aquaporin 5 expression in mouse lung epithelial cells. J Biol Chem. 2001;276:18657–64.PubMedCrossRef
30.
Woo J, Lee J, Kim MS, et al. The effect of aquaporin 5 overexpression on the Ras signaling pathway. Biochem Biophys Res Commun. 2008;367:291–8.PubMedCrossRef
31.
Woo J, Chae YK, Jang SJ, et al. Membrane trafficking of AQP5 and cAMP dependent phosphorylation in bronchial epithelium. Biochem Biophys Res Commun. 2008;366:321–7.PubMedCrossRef
32.
Yan C, Yang J, Shen L, Chen X. Inhibitory effect of Epigallocatechin gallate on ovarian cancer cell proliferation associated with aquaporin 5 expression. Arch Gynecol Obstet. 2012;285:459–67.PubMedCrossRef
Metadata
Title
AQP5 Expression Predicts Survival in Patients with Early Breast Cancer
Authors
Soo Jung Lee, MD, PhD
Yee Soo Chae, MD, PhD
Jong Gwang Kim, MD, PhD
Wan Wook Kim, MD
Jin Hyang Jung, MD, PhD
Ho Yong Park, MD, PhD
Ji Yun Jeong, MD
Ji-Young Park, MD, PhD
Hyun Jun Jung, PhD
Tae-Hwan Kwon, MD, PhD
Publication date
01-02-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 2/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-3317-7

Other articles of this Issue 2/2014

Annals of Surgical Oncology 2/2014 Go to the issue

Gynecologic Oncology

Progress in Survival Outcomes in Patients with Advanced Ovarian Cancer Treated by Neo-Adjuvant Platinum/Taxane-Based Chemotherapy and Late Interval Debulking Surgery

Gastrointestinal Oncology

Determinants of Response to Neoadjuvant Chemotherapy for Esophageal Cancer Using 18F-fluorodeoxiglucose Positron Emission Tomography (18F-FDG-PET)

Melanomas

Resection of Residual Disease after Isolated Limb Infusion (ILI) Is Equivalent to a Complete Response after ILI-Alone in Advanced Extremity Melanoma

Breast Oncology

Reply to “Anti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on ‘Early Assessment of Axillary Response with 18F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Ann Surg Oncol. 2013;20(7):2227–35’”

Hepatobiliary Tumors

Prognostic Biomarkers in Patients with Resected Cholangiocarcinoma: A Systematic Review and Meta-analysis

Colorectal Cancer

Salvage Surgery for Residual Primary and Locally Recurrent Anal Squamous Cell Carcinoma After Chemoradiotherapy in HIV-positive Individuals